Depression in patients with cardiovascular disease

Česká verzia

Authors: V. Pidrman
Published in the journal: Kardiol Rev Int Med 2007, 9(3): 165-169

Summary

Depression in patients with cardiovascular disease. The paper describes the epidemiology of and further links between the occurrence of depression and cardiovascular disease. Direct links between the two diseases in both the psychic and biological sphere are pointed out. The second part of the paper describes anti-depression therapy and focuses on the characteristics, advantages and possible risks of the different groups of anti-depression drugs.

Keywords:
depression – anti-depression drugs – SSRI – selective serotonin reuptake inhibitors – cardiovascular disease

Zdroje

1. Malzberg B. Mortality among patients with involuntional melancholia. Am J Psychiatry 1937; 93: 1231–1238.

2. Alexopoulos GS, Katz IR, Reynolds CF et al. Pharmacotherapy of depressive disorders in older patients. New York: Comprehensive NeuroScience 2001: 76.

3. Bazire S. Psychotropic drug directory 2002. Jesses Farm: Mark Alen Publishing 2002: 340.

4. Bednar MM, Harrigan EP, Anziano et al. The QT-interval. Prog Cardiovask Dis 2001; 43(5): 1–45.

5. Braunwald E. Harisson’s principles of internal medicine. New York: McGraw-Hill Book Comp. l998: 2918.

6. American Medical Directors Association. Clinical Practice Guideline. Depression 1996.

7. Cozza KL, Armstrong SC. The cytochrome P450 system. Drug interaction principles for medical practice. Washington: American Psychiatric Publishing 2001: 262.

8. Flint AJ, Rifat SL. Maintenance tretment for recurrent depression in late life: a four year outcome study. Am J Geriatr Psychiatry 2000; 8(2): 112–116.

9. Goodyer JM. Unipolar depression. New York: Oxford University Press 2003: 212.

10. Gottfried CG, Karlsson I. Depression in later life. Oxford: OCC l997: 58.

11. Henn F, Sartorius N, Helmchen H, Lauter H. Contemporary psychiatry. Berlin: Springer 2001: 2258.

12. Grossberg GT, Stehelin HB, Mesina JC et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of mediacations. Int J Geriatr Psychiatry 2002; 15: 242–247.

13. Jacobson SA, Preis RW, Greenblatt DJ. Handbook of geriatric psychopharmacology. Washington: American Psychiatric

Publishing 2002: 445.

14. Malhi GS, Bridges PK. Management of depression. London: Marin Dunitz l998: 130.

15. Murray CJL, Lopez AD. The global burden of disease. Cambridge: Harvard University Press l996.

16. Pidrman V. Deprese a kardiovaskulární onemocnění. 3. ed. Praha: Maxdorf 2004: 68.

17. Pidrman V, Bouček J, Kryl M. Deprese v interní medicíně. Praha: PCP 2003: 46.

18. Preskorn SH. Outpatient management of depression. Caddo: Professional Communication l999: 256.

19. Reuben BD, Herr KA, Pacala JT et al. Geriatrics. Malden: Blackwell Publishing 2003: 240.

20. Roose SP, Spatz BS. Treating depression in patients with ischemic heart disease. Drug Saf l999; 20: 459–465.

21. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104: 1894–1898.

22. Shiloh R, Nutt D, Weizman A. Atlas of psychotropic pharmacotherapy. London: Martin Dunitz 2000: 235.

23. Schaltberg AF, Cole JO, DeBatista C. Manual of clinical psychopharmacology. Washington: American Psychiatric

Publishing 2003: 700.

24. Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drug Aging 2001; 18(5): 355–368.

25. Spar EJ, La Rue A. Concise guide to geriatric psychiatry. Washington: American Psychiatric Publishing 2002: 372.

26. Stahl MS. Essential psychopharmacology. Neuroscientific basis and practical applications. Cambridge: Cambridge University Press 2002: 602.

27. Thorpe L, Whitney DK, Kutcher SP et al. Clinical Guidelines for the treatment of depressive disorders. VI. Special populations.

Can J Psychiatry 2001; 46(Suppl 1): 63S–76S.